PBM Rebates
RegulationWatch reporting on pbm rebates matters involving US pharmaceutical manufacturers, PBMs and healthcare companies, newest first.
- 340B Program (1)
- Anti-Kickback Statute (3)
- Antitrust (6)
- Controlled Substances Act (3)
- Drug Pricing (8)
- Drug Promotion (1)
- FTC Enforcement (2)
- FTC Report (1)
- False Claims Act (9)
- Marketing Fraud (2)
- Medicare Advantage (1)
- Medicare Negotiation (1)
- Merger Conditions (1)
- Off-Label Promotion (1)
- Opioid Distribution (1)
- Opioid Litigation (4)
- PBM Oversight (1)
- PBM Rebates (7)
- Patent Litigation (1)
- State Enforcement (4)
- PBM Rebates
Express Scripts settled the insulin case without paying a cent or admitting a thing.
The FTC's order changes how Cigna's pharmacy benefit manager behaves from here. It returns nothing for the years the agency says list prices were inflated.
- PBM Rebates
Vyndamax made $6 billion in 2025 with a cheaper rival on the market. The rebate system is built to protect incumbents like Pfizer.
Pharmacy benefit managers are paid more when list prices and rebates are higher. Two FTC settlements and a federal reform law have not yet changed that, and Pfizer's contracts stay secret.
- PBM Rebates
Sixth Circuit keeps Kentucky opioid case against PBMs in federal court
The Sixth Circuit reversed an order returning Kentucky's opioid lawsuit against Express Scripts and OptumRx to state court. The ruling addressed jurisdiction, without deciding liability.
- PBM Rebates
Caremark's "$8.5 billion" settlement is a projection. CVS pays nothing.
The FTC closed its insulin case against CVS's pharmacy benefit manager with conduct terms the company says it largely follows already.
- PBM Rebates
Louisiana files federal antitrust suit against Express Scripts and Ascent Health Services
Louisiana Attorney General Liz Murrill has sued Express Scripts, Inc. and its group purchasing affiliate Ascent Health Services LLC in federal court, alleging a conspiracy with Prime Therapeutics to fix pharmacy reimbursement rates. The complaint also alleges that manufacturer rebates were reclassified as fees and that patients were steered to Express Scripts-affiliated pharmacies.
- PBM Rebates
Missouri sues 19 PBMs and insulin makers over alleged pricing scheme
Missouri Attorney General Catherine Hanaway has sued 19 pharmacy benefit manager and drug manufacturer defendants, alleging a scheme to inflate insulin prices in violation of the Missouri Merchandising Practices Act. The state seeks injunctive relief, restitution, damages and disgorgement.
- PBM Rebates
CVS Caremark becomes second major PBM to settle FTC insulin rebating case
The FTC reached a proposed consent order with CVS Health's Caremark Rx and its group purchasing organisation Zinc Health Services, resolving allegations that rebate practices inflated insulin list prices. The FTC says the terms will deliver $8.5 billion in consumer savings over a decade, plus up to $4.5 billion through point-of-sale rebates.
